Clinical Data of the Two Groups at Initial Evaluation
| . | 32P Alone (on 242 cases) . | 32P and Maintenance Therapy (on 219 cases) . |
|---|---|---|
| Sex ratio (M/F) | 1/1.29 | 1/0.97 |
| Median age (yr) | ||
| Male | 72 | 73 |
| Female | 75 | 75 |
| Hematologic criteria (% of the cases) | ||
| Splenomegaly | 37 | 35 |
| Excess of the three cell lines without splenomegaly | 35 | 36 |
| Excess of red blood cells and granulocytes only | 7 | 6 |
| Excess of red blood cells and platelets only | 16 | 15 |
| Excess of red blood cells only (with low Epo value and/or spontaneous BFU-E growth) | 5 | 8 |
| Vascular risk | ||
| High risk* | 36 | 35 |
| Relatively low risk† | 21 | 28 |
| No identified risk‡ | 43 | 37 |
| . | 32P Alone (on 242 cases) . | 32P and Maintenance Therapy (on 219 cases) . |
|---|---|---|
| Sex ratio (M/F) | 1/1.29 | 1/0.97 |
| Median age (yr) | ||
| Male | 72 | 73 |
| Female | 75 | 75 |
| Hematologic criteria (% of the cases) | ||
| Splenomegaly | 37 | 35 |
| Excess of the three cell lines without splenomegaly | 35 | 36 |
| Excess of red blood cells and granulocytes only | 7 | 6 |
| Excess of red blood cells and platelets only | 16 | 15 |
| Excess of red blood cells only (with low Epo value and/or spontaneous BFU-E growth) | 5 | 8 |
| Vascular risk | ||
| High risk* | 36 | 35 |
| Relatively low risk† | 21 | 28 |
| No identified risk‡ | 43 | 37 |
High risk is more frequent in male than in female patients (46% v 27%; P < .001).
Abbreviation: Epo, erythropoietin.
History of stroke, myocardial attack, severe leg arteritis, pulmonary embolism.
Angina, noncontrolled arterial hypertension, phlebitis without embolism, and diabetes.
No vascular antecedent.